Cheaper Ozempic: How Generic Semaglutide Will Transform Obesity Care in India

India is poised for a significant shift in obesity and diabetes care as generic versions of semaglutide, the active ingredient in Ozempic and Wegovy, grow available following the expiration of the key patent on March 20, 2026. This patent expiry is expected to drive down prices by 40% to 50%, potentially making the drug accessible to a much wider population and sparking competition among Indian pharmaceutical companies.

The Rise of Generic Semaglutide in India

At least five Indian pharmaceutical firms – Mankind Pharma, Ajanta Pharma, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Lupin – are preparing to launch generic semaglutide immediately after the patent expires. These medications are anticipated to be priced around ₹5,000 for a weekly dose, a substantial reduction compared to the current cost of Novo Nordisk’s branded Ozempic. Mankind Pharma plans to launch its version, branded as Samakind, in March 2026.

Market Growth and Economic Impact

The Indian GLP-1 (glucagon-like peptide-1) drug market is projected to grow significantly, from approximately ₹10 billion in 2025 to as much as ₹50 billion by 2030. This growth is fueled by a rising prevalence of obesity and lifestyle-related metabolic illnesses in India, where over 1.4 billion people reside. The country’s robust pharmaceutical industry, known for its generic drug production, is well-positioned to capitalize on this opportunity.

Expanding Healthcare Services

The anticipated increase in semaglutide accessibility is prompting hospitals, telehealth firms, and clinics to expand their obesity-focused services. Hospital chains like Apollo Health & Lifestyle and Fortis Healthcare are establishing or expanding dedicated obesity management centers, staffed with a multidisciplinary team of healthcare professionals. Diagnostic networks, such as Tata 1MG Technologies, are offering discounted obesity screening packages, and online pharmacies are facilitating access to semaglutide through teleconsultations.

Patient Support and Regulation

Recognizing the importance of comprehensive care, Dr. Reddy’s is exploring patient support programs alongside its generic semaglutide launch, while Cipla is collaborating with obesity clinics in smaller towns to enhance treatment management. The Indian drug regulator has responded to the growing interest in obesity treatments by banning advertising and promotional campaigns related to weight-loss programs, aiming to curb aggressive commercial messaging.

Competition and Market Dynamics

Mankind Pharma aims to be among the first to launch its generic semaglutide, focusing on affordability and accessibility. The company will compete with generics from Sun Pharma, Zydus Lifesciences, Dr. Reddy’s, Natco, Ajanta, and Torrent. The Indian market is unique, with healthcare largely paid for out-of-pocket, emphasizing the require for hospitals and clinics to design long-term supervision packages for patients.

Key Takeaways

• The expiration of the semaglutide patent in India on March 20, 2026, will lead to the availability of cheaper generic versions.
• Generic semaglutide is expected to be priced around ₹5,000 per weekly dose, significantly lower than branded Ozempic.
• The Indian GLP-1 drug market is projected to grow substantially, reaching up to ₹50 billion by 2030.
• Hospitals and clinics are expanding obesity-focused services to meet the anticipated increase in demand.
• Regulatory measures are in place to limit aggressive marketing of weight-loss drugs.